Actively Recruiting

Phase 2
Phase 3
Age: 2Years - 17Years
All Genders
NCT06328608

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Led by Chiesi Farmaceutici S.p.A. · Updated on 2026-03-19

22

Participants Needed

12

Research Sites

296 weeks

Total Duration

On this page

Sponsors

C

Chiesi Farmaceutici S.p.A.

Lead Sponsor

I

ICON plc

Collaborating Sponsor

AI-Summary

What this Trial Is About

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease.

CONDITIONS

Official Title

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Boys and girls aged 2 to 7 years (Cohort A), 8 to 12 years (Cohort B), or 13 to less than 18 years (Cohort C)
  • Confirmed diagnosis of Fabry disease
  • Presence of at least one characteristic feature of Fabry disease: neuropathic pain, cornea verticillata, or clustered angiokeratoma
  • History of Fabry pain, including Fabry crises or chronic pain
  • Clinical condition requiring enzyme replacement therapy as judged by the investigator
  • Provision of informed consent from legal guardian
Not Eligible

You will not qualify if you...

  • Estimated glomerular filtration rate (eGFR) below 80 mL/min/1.73 m2 at screening
  • History of life-threatening hypersensitivity reactions to other enzyme replacement therapies or any component of the study drug
  • Starting or changing dose of ACE inhibitor or angiotensin II receptor blocker within four weeks before screening
  • Urine protein to creatinine ratio (UPCR) over 0.5 g/g if not treated with ACE inhibitor or ARB
  • Currently taking another investigational drug
  • History of acute kidney injury within 12 months before screening
  • History of kidney dialysis or transplantation
  • History or current malignancy requiring treatment
  • Severe or unstable heart disease within six months before screening
  • Positive test for COVID-19 within three months before screening
  • Any medical, emotional, behavioral, or psychological condition interfering with study compliance
  • (Stage I only) Female participants
  • (Stage I only) Non-classic form of Fabry disease
  • (Stage I only) Treatment for Fabry disease within six months before screening
  • (Stage I only) Positive for anti-PRX-102 antibodies at screening
  • (Stage II only) Unwillingness to stop current enzyme replacement therapy before baseline
  • (Stage II only) Females who are pregnant, breastfeeding, or of childbearing potential unwilling to use reliable contraception until 30 days after last infusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

Phoenix Children's

Phoenix, Arizona, United States, 85016

Actively Recruiting

2

Emory Genetics Clinical Trials Center

Atlanta, Georgia, United States, 30322

Actively Recruiting

3

University of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

4

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Not Yet Recruiting

5

University of Utah

Salt Lake City, Utah, United States, 84108

Actively Recruiting

6

Lysosomal and Rare Disorders Research and Treatment Center Inc

Fairfax, Virginia, United States, 22030

Not Yet Recruiting

7

UK für Kinder- und Jugendheilkunde der PMU Salzburg

Salzburg, Austria

Actively Recruiting

8

Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin

Bordeaux, France, 33076

Actively Recruiting

9

Hopital Arnaud de Villeneuve

Montpellier, France

Actively Recruiting

10

Haukeland Universitetssjukehus

Bergen, Norway, 5021

Actively Recruiting

11

Hospital Clinico Universitario De Santiago De Compostela

Santiago de Compostela, Spain

Actively Recruiting

12

Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom

Not Yet Recruiting

Loading map...

Research Team

C

Chiesi Clinical Trial

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease | DecenTrialz